The Mayo Clinic Center for the Individual Treatment of Alcohol Dependence (CITA) is a P20 exploratory/ developmental alcohol research center proposal with the over-arching theme of using translational research strategies to create a new research center with the capacity to originate and conduct pharmacogenomic probe studies to differentiate treatment responses in patients with severe alcohol dependence. This new center would build upon an already existing team of researchers conducting synergistic clinical and preclinical translational research in a major academic medical center with resources already devoted to translation research and training in the provision of individualized clinical care. The importance of the goal of being able to provide individualized medical treatment for alcohol dependence has become increasingly apparent. This is specifically true related to the identification of variable responses to antidipsotropic medications. Whereas some individuals have excellent responses, there are clearly many who do not. The ability to be able to reliably differentiate those who will respond to an effective treatment has multiple benefits. The efficient identification of treatment responders would result in enormous saving of both cost and personal suffering. Another potential benefit would be the development of new medications with very targeted indications that would be uniquely helpful for selected individuals who could be identified by low cost genotyping. The feasibility of establishing this innovative approach to the study of alcohol treatment is dependent on close collaboration between the investigators of the P20 Center and the scientists who are currently working as part of the Pharmacogenomic Research Network team (PGRN) and the Advanced Genomic Technology Center (AGTC). Additionally, the broad resources of the Center for Translational Science Activities (CTSA) at the Mayo Clinic will provide a strong foundation from which to build translational research studies utilizing state-of-the-art genotyping technology. Four exploratory projects are described that foster translation from preclinical to clinical investigations. Two projects explore the relationship between genetic variation and response to acamprosate administration. The first uses a mouse model while the second is a pharmacogenomic probe study using a prospectively defined sample of subjects with alcohol dependence. The remaining two projects use magnetic resonance spectroscopy to explore the relationship between glutamate concentrations in the central nervous system and acamprosate treatment in mice and in patients treated for alcohol dependence.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Exploratory Grants (P20)
Project #
1P20AA017830-01
Application #
7547818
Study Section
Special Emphasis Panel (ZAA1-BB (80))
Program Officer
Litten, Raye Z
Project Start
2009-09-30
Project End
2011-08-31
Budget Start
2009-09-30
Budget End
2010-08-31
Support Year
1
Fiscal Year
2009
Total Cost
$1,231,613
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Germany, Caroline E; Reker, Ashlie N; Hinton, David J et al. (2018) Pharmacoproteomics Profile in Response to Acamprosate Treatment of an Alcoholism Animal Model. Proteomics 18:e1700417
Croarkin, Paul E; Luby, Joan L; Cercy, Kelly et al. (2017) Genetic Risk Score Analysis in Early-Onset Bipolar Disorder. J Clin Psychiatry 78:1337-1343
Nassan, Malik; Li, Qingqin; Croarkin, Paul E et al. (2017) A genome wide association study suggests the association of muskelin with early onset bipolar disorder: Implications for a GABAergic epileptogenic neurogenesis model. J Affect Disord 208:120-129
Frye, Mark A; Hinton, David J; Karpyak, Victor M et al. (2016) Elevated Glutamate Levels in the Left Dorsolateral Prefrontal Cortex Are Associated with Higher Cravings for Alcohol. Alcohol Clin Exp Res 40:1609-16
Karpyak, Victor M; Biernacka, Joanna M; Geske, Jennifer R et al. (2016) Gender-specific effects of comorbid depression and anxiety on the propensity to drink in negative emotional states. Addiction 111:1366-75
Ho, Ada Man-Choi; Qiu, Yanyan; Jia, Yun-Fang et al. (2016) Combined Effects of Acamprosate and Escitalopram on Ethanol Consumption in Mice. Alcohol Clin Exp Res 40:1531-9
Scola, Gustavo; McNamara, Robert K; Croarkin, Paul E et al. (2016) Lipid peroxidation biomarkers in adolescents with or at high-risk for bipolar disorder. J Affect Disord 192:176-83
Croarkin, Paul E; Nakonezny, Paul A; Wall, Christopher A et al. (2016) Transcranial magnetic stimulation potentiates glutamatergic neurotransmission in depressed adolescents. Psychiatry Res Neuroimaging 247:25-33
Frye, Mark A; Hinton, David J; Karpyak, Victor M et al. (2016) Anterior Cingulate Glutamate Is Reduced by Acamprosate Treatment in Patients With Alcohol Dependence. J Clin Psychopharmacol 36:669-674
Nassan, Malik; Nicholson, Wayne T; Elliott, Michelle A et al. (2016) Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine. Mayo Clin Proc 91:897-907

Showing the most recent 10 out of 48 publications